← 返回

载顺铂金纳米壳介导化疗-光热疗法抑制原发性和远端肺癌生长

英文原题:Cisplatin-loaded gold nanoshells mediate chemo-photothermal therapy against primary and distal lung cancers growth.

查看英文原题

Cisplatin-loaded gold nanoshells mediate chemo-photothermal therapy against primary and distal lung cancers growth.

PubMed 2022/12/28(内容时间) Biomed Pharmacother

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肺癌是全球癌症死亡最常见的原因。过去几十年,手术、放疗、化疗和免疫治疗药物的进展已取得进步,但肺癌的预后仍然很差。在本研究中,我们开发了负载顺铂(CDDP)的人血清白蛋白(HSA)基金纳米壳(HCP@GNSs),用于协同化学-光热治疗(chemo-PTT)。HCP@GNSs不仅作为化疗的药物纳米载体,还作为PTT的优良介质,在近红外(NIR)激光照射下可表现出足以进行光热消融的温度升高。HCP@GNSs具有高度的生物相容性和血液相容性纳米载体特性,而HCP@GNSs加NIR暴露产生的协同chemo-PTT显示出比单独HCP@GNSs或PTT更强的细胞毒性效应,尤其是在低CDDP浓度下。体内分析表明,HCP@GNSs介导的chemo-PTT增加了肿瘤中的坏死,以实现高肿瘤清除率且无不良副作用。

此外,HCP@GNSs介导的chemo-PTT诱导远端肿瘤中树突状细胞、B细胞和自然杀伤T细胞的募集,从而抑制肿瘤生长。

因此,负载CDDP的HCP@GNSs可能是未来用于治愈性肺癌治疗的潜在纳米药物候选者。

展开英文摘要原文

Lung cancer is the most common cause of cancer mortality worldwide. The advances in surgery, radiotherapy, chemotherapeutic and immunotherapeutic drugs have progressed in the past decades, but the prognosis of lung cancer is still poor. In this study, we developed cisplatin (CDDP)-loaded human serum albumin (HSA)-based gold nanoshells (HCP@GNSs) for synergistic chemo-photothermal therapy (chemo-PTT). The HCP@GNSs not only acted as drug nanocarriers for chemotherapy but also serve as a superior mediator for PTT, which could exhibit a temperature increase upon a near infrared (NIR) laser exposure that was sufficient for photothermal ablation.

HCP@GNSs were highly biocompatible and hemocompatible nanocarriers, while the synergistic chemo-PTT resulting from HCP@GNSs plus NIR exposure displayed stronger cytotoxicity effect than HCP@GNSs or PTT alone, especially at a low CDDP concentration. In vivo analysis demonstrated that HCP@GNSs-mediated chemo-PTT increased necrosis in tumors to achieve a high tumor clearance rate with no adverse side effects.

Moreover, HCP@GNSs-medicated chemo-PTT induced the recruitment of dendritic cells, B-cells, and natural killer T-cells in distal tumors to inhibit the growth of the tumors.

Therefore, the CDDP-loaded HCP@GNSs may be a potential nanomedicine candidate for curative lung cancer treatment in the future.

论文信息

作者
Yang SJ、Pai JA、Shieh MJ、Chen JL、Chen KC
第一作者单位
Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei 100, Taiwan.Taiwan
通讯作者单位
Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei 100, Taiwan; Department of Surgery, National Taiwan University Hospital and College of Medicine, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. Electronic address: 010288@ntuh.gov.tw.Taiwan
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2023 Feb
原文标识
PubMed 36584428 · DOI 10.1016/j.biopha.2022.114146